Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer

Drug Safety

Volumn 32, Issue 9, 2009, Pages 717-734

  Theou Anton, Nathalie ^a   Faivre, Sandrine ^a   Dreyer, Chantal ^a   Raymond, Eric ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTACID AGENT; ANTIEMETIC AGENT; ANTIHYPERTENSIVE AGENT; BETAMETHASONE DIPROPIONATE; BEVACIZUMAB; CAPECITABINE; CYTARABINE; DOLASETRON MESILATE; DOMPERIDONE; DOXORUBICIN; DRUG METABOLITE; FLUOROURACIL; GRANISETRON; IMATINIB; INTERLEUKIN 2; LEVOTHYROXINE; LEVOTHYROXINE SODIUM; LOPERAMIDE; ONDANSETRON; PLACEBO; SALICYLIC ACID; SORAFENIB; STEM CELL FACTOR; SU 012662; SUNITINIB; THYROTROPIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1;

ADENOCARCINOMA; ANEMIA; ANOREXIA; ASTHENIA; BRADYCARDIA; CANCER RESISTANCE; CANCER SURVIVAL; CHEILITIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DISGEUSIA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY SKIN; DYSPEPSIA; EDEMA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENITAL BLEEDING; GINGIVA BLEEDING; GLOSSODYNIA; HAIR DISCOLORATION; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEARTBURN; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MELANOMA; MOUTH PAIN; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHRECTOMY; NEUROENDOCRINE TUMOR; NEUTROPENIA; NONHUMAN; PARESTHESIA; PATIENT COMPLIANCE; PATIENT COUNSELING; PRIORITY JOURNAL; QT PROLONGATION; RASH; RECOMMENDED DRUG DOSE; RECTUM HEMORRHAGE; REVIEW; RISK ASSESSMENT; SARCOMA; SIDE EFFECT; SKIN DISCOLORATION; SKIN TINGLING; SKIN TOXICITY; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; THYROID CANCER; TORSADE DES POINTES; TREATMENT RESPONSE; TUMOR BLEEDING; UPPER GASTROINTESTINAL BLEEDING; VESICULAR RASH; VOMITING; XEROSTOMIA;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; GASTROINTESTINAL NEOPLASMS; HUMANS; INDOLES; KIDNEY NEOPLASMS; PYRROLES; RISK ASSESSMENT;

EID: 68849113367     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/00002018-200932090-00003     Document Type: Review

References (79)

1. Faivre S, Djelloul S, Raymond E. New paradigms in anti-cancer therapy: targeting multiple signalling pathways with kinase inhibitors. Semin Oncol 2006;33: 407-20
2. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon a in metastatic renal-cell carcinoma. N Engl J Med 2007;356: 115-24
3. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. Lancet 2006;368: 1329-38
4. Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007 Mar 1;13(5): 1367-73
5. Faivre S, Demetri G, Sargent W, et al. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007 Sep; 6 (9): 734-45
6. Duensing A, Heinrich MC, Fletcher CD, et al. Biology of gastrointestinal stromal tumors: KIT mutations and beyond. Cancer Invest 2004;22: 106-16
7. Naoe T, Kiyoi H. Normal and oncogenic FLT3. Cell Mol Life Sci 2004;61: 2932-8
8. Ichihara M, Murakumo Y, Takahashi M. RET and neuroendocrine tumors. Cancer Lett 2004;204: 197-211
9. Sapi E. The role of CSF-1 in normal physiology of mammary gland and breast cancer: an update. Exp Biol Med 2004;229: 1-11
10. Baratte S, Sarati S, Frigerio E, et al. Quantitation of SU11248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semiautomated liquid-liquid extraction. J Chromatogr A 2004 Jan 23;1024(1-2): 87-94
11. Bello CL, Sherman L, Zhou J, et al. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 2006;17: 353-8
12. De Mulder PH, Roigas J, Gillessen S, et al. A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine refractory metastatic renal cell carcinoma (mRCC). American Society of Clinical Oncology 42nd Annual Meeting; 2006 Jun 2-6; Atlanta (GA)
13. George S, Casali PG, Blay J, et al. Phase II study of sunitinib administered in a continuous daily dosing regimen in patients (pts) with advanced GIST. American Society of Clinical Oncology 42nd Annual Meeting; 2006 Jun 2-6; Atlanta (GA)
14. Blay JY, George S, Casali PG, et al. Clinical benefit of continuous daily dosing of sunitinib in patients (pts) with advanced gastrointestinal stromal tumor (GIST) [abstract]. Ann Oncol 2006;17 Suppl. 9: 163
15. Escudier B, Roigas J, Gillessen S, et al. Continuous daily administration of sunitinib malate (SU11248): a phase II study in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC) [abstract]. Ann Oncol 2006;17 Suppl. 9: 144
16. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9: 327-37
17. Abrams TJ, Lee JB, Murray LJ, et al. SU11248 inhibits KIT and platelet derived growth factor receptor b in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2: 471-8
18. Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003;2: 1011-21
19. Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003;20: 757-66
20. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmaco-kinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24: 25-35
21. Motzer RJ, Hoosen S, Bello CL, et al. Sunitinib malate for the treatment of solid tumors: a review of current clinical data. Expert Opin Investig Drugs 2006;15: 553-61
22. Lam JS, Leppert JT, Belldegrun AS, et al. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 2005;23: 202-12
23. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22: 454-63
24. Rohrmann K, Staehler M, Haseke N, et al. Immunotherapy in metastatic renal cell carcinoma. World J Urol 2005;23: 196-201
25. Motzer RJ, Bander NH, Nanus DM, et al. Renal-cell carcinoma. N Engl J Med 1996;335: 865-75
26. Patel PH, Chaganti RSK, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 2006;94: 614-9
27. Kamura T, Sato S, Iwai K, et al. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci U S A 2000;97: 10430-5
28. Wang GL, Semenza GL. General involvement of hypoxiainducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A 1993;90: 4304-8
29. Bardos JL, Aschcroft M. Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays 2004;26: 262-9
30. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24: 16-24
31. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295: 2516-24
32. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370: 2103-11
33. Heng DY, Chi KN, Murray N, et al. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer 2009 Feb 15;115(4): 776-83
34. Margulis V, Matin SF, Tannir N, et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. Urol Oncol 2009 Jan-Feb; 27 (1): 108-9
35. Heinrich MC, Corless MC, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21: 4342-9
36. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22: 3813-25
37. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005 Aug 10;23(23): 5357-64
38. Blanke CD, Corless CL. State-of-the art therapy for gastrointestinal stromal tumors. Cancer Invest 2005;23: 274-80
39. Demetri GD, Von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347: 472-80
40. Van Glabbeke M, Verweij J, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastro intestinal Trials Group study. J Clin Oncol 2005;23:5795-804
41. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomised trial. Lancet 2004;364: 1127-34
42. Maki RG, Fletcher JA, Heinrich MC, et al. SU11248 in patients with imatinib-resistant GIST: results from a continuation trial. American Society of Clinical Oncology 41st Annual Meeting; 2005 May 13-17; Orlando (FL)
43. Demetri GD, Huang X, Garrett CR, et al. Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure [abstract]. J Clin Oncol 2008 May 20;26 Suppl.: 10524
44. Reichardt P, Kang Y, Ruka W, et al. Detailed analysis of survival and safety with sunitinib (SU) in a worldwide treatment-use trial of patients with advanced GIST [abstract]. J Clin Oncol 2008 May 20;26 Suppl.: 10548
45. Blackstein M, Huang X, Demetri GD, et al. Investigation of soluble kit as a potential surrogate marker for ttp in sunitinib-treated patients with GIST [abstract]. Ann Oncol 2007;18(Suppl. 7): VII16
46. Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008 Nov 20;26(33): 5352-9
47. SUTENT product monograph [online]. Available from URL: http://www.pfizer.ca/english/our%20products/prescription%20pharmaceuticals/ default.asp?s=1&id=32&doc=enmonograph [Accessed 2009 Jun 16]
48. Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother 2003;37: 1276-86
49. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007;99: 81-3
50. Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006;145: 660-4
51. Shaheen PE, Tamaskar IR, Salas RN, et al. Thyroid function tests (TFTs) abnormalities in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib [abstract]. Proc Am Soc Clin Oncol 2006;24: 4605
52. Schoeffski P, Wolter P, Himpe U, et al. Sunitinib-related thyroid dysfunction: a single-center retrospective and prospective evaluation [abstract]. Proc Am Soc Clin Oncol 2006;24: 3092
53. Grossmann M, Premaratne E, Desai J, et al. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) 2008 Oct; 69 (4): 669-72
54. Sica DA. Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol 2006;24: 1329-31
55. Willett CG, Boucher Y, Di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10: 145-7
56. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349: 427-34
57. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004;10: 6388-92S
58. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356: 125-34
59. Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006;24: 1363-9
60. Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of sunitinib activity [abstract]. Ann Oncol 2007 Jun; 18 (6): 1117
61. Dougall HT, McLay J. A comparative review of the adverse effects of calcium antagonists. Drug Saf 1996;15: 91-106
62. Cross BW, Kirby MG, Miller S, et al. A multicentre study of the safety and efficacy of amlodipine in mild to moderate hypertension. Br J Clin Pract 1993;47: 237-40
63. Pedrinelli R, Dell'Omo G, Melillo E, et al. Amlodipine, enalapril, and dependent leg edema in essential hypertension. Hypertension 2000;35: 621-5
64. Ruka W, Rutkowski P, Nowecki Z, et al. Emergency surgery due to complications during molecular targeted therapy in advanced gastrointestinal stromal tumors (GIST). Society of Surgical Oncology 61st Annual Cancer Symposium, Chicago (IL), 13-16 March 2008 [abstract]. Ann Surg Oncol 2008;15 suppl. 2: 82
65. Telli ML, Witteles RM, Fisher GA, et al. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 2008;19(9): 1613-8
66. Khakoo AY, Kassiotis CM, Tannir N, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008 Jun 1;112(11): 2500-8
67. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007 Dec 15;370(9604): 2011-9
68. Wolter P, Stefan C, Decallonne B, et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 2008 Aug 5;99(3): 448-54
69. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6: 491-500
70. Lacouture ME, Reilly LM, Gerami P, et al. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008 Jun 10;19(11): 1955-61
71. Tsai KY, Yang CH, Kuo TT, et al. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol 2006;24: 5786-8
72. Alexandrescu DT, Vaillant JG, Dasanu CA. Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors. Clin Exp Dermatol 2007;32: 71-4
73. Botchkareva NV, Khlgatian M, Longley BJ, et al. SCF/KIT signaling is required for cyclic regeneration of the hair pigmentation unit. FASEB J 2001;15: 645-58
74. Hemesath TJ, Price ER, Takemoto C, et al. MAP kinase links the transcription factor microphthalmia to KIT signalling in melanocytes. Nature 1998;391: 298-301
75. Moss KG, Toner GC, Cherrington JM, et al. Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther 2003;307: 476-80
76. George S, Blay JY, Casali PG, et al. Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: updated efficacy, safety, PK and pharmacodynamic analysis [abstract]. J Clin Oncol 2008 May 20;26: 10554
77. Houk BE, Bello CL, Michaelson MD, et al. Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): a population pharmacokinetic/ pharmacodynamic (PKPD) approach [abstract]. J Clin Oncol 2007;25: 5027
78. van der Veldt AA, Boven E, Helgason HH, et al. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 2008;99: 259-65
79. Shukla S, Robey RW, Bates SE, et al. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ABC transporters, P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 2009 Feb; 37 (2): 359-65